Form 4 for FDMT 4D Molecular Therapeutics, Inc.
Accepted 2023-01-23 00:00:00 ET · period of report 2023-01-19 · accession 0001567619-23-001163 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-01-23 | 2023-01-19+ | FDMT | Kirn David | CEO, Dir | S - Sale | $20.10 | -19.5K | 1.90M | -1% | -$392.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-20 | S | D | 8,625 | $20.19 | 1,893,599 | D | — | — | (F3) The transaction was executed in multiple trades in prices ranging from $20.01 to $20.41, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2023-01-19 | S | D | 10,899 | $20.03 | 1,902,224 | D | — | — | (F2) The transaction was executed in multiple trades in prices ranging from $19.83 to $20.28, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |